诺和诺德Novo Nisk（NVO）2024年第三季度投资者活动PPT「NYSE」（英文版）（163页）.pdf

1、1Investor presentation First nine months of 2024Novo Nordisk a focused healthcare companyInvestor presentationFirst nine months of 2024RAFAEL VALVERDERAFAEL VALVERDERafael lives with obesityMexicoABIGAIL CONIAHABIGAIL CONIAHAbigail lives with obesityUnited KingdomNovo NordiskInvestor presentation Fi

2、rst six months of 20242AgendaProgress on Strategic Aspirations 2025FinancialsInnovation and therapeutic focusCommercial executionAgendaNovo NordiskInvestor presentation First nine months of 20243Forward-looking statementsNovo Nordisks reports filed with or furnished to the US Securities and Exchange

3、 Commission(SEC),including the statutory Annual Report 2023 and Form 20-F,which both were filed with the SEC in January 2024 in continuation of the publication of the Annual Report 2023,this presentation,and written information released,or oral statements made,to the public in the future by or on be

4、half of Novo Nordisk,may contain forward-looking statements.Words such as believe,expect,may,will,plan,strategy,prospect,foresee,estimate,project,anticipate,can,intend,target and other words and terms of similar meaning in connection with any discussion of future operating or financial performance i

5、dentify forward-looking statements.Examples of such forward-looking statements include,but are not limited to:Statements of targets,plans,objectives or goals for future operations,including those related to Novo Nordisks products,product research,product development,product introductions and product

6、 approvals as well as cooperation in relation thereto,Statements containing projections of or targets for revenues,costs,income(or loss),earnings per share,capital expenditures,dividends,capital structure,net financials and other financial measures,Statements regarding future economic performance,fu